December 16, 2016
A Japanese patent (6060073) was issued for JN Biosciences' humanized anti-CD122 IgG antibody HuABC2, which has been developed for treatment of autoimmune disease and allograft rejection.
October 12, 2016
A European patent (2560994) was issued for JN Biosciences' humanized anti-CD122 IgG antibody HuABC2.
August 17, 2016
A Chinese patent (102939305) was issued for JN Biosciences' humanized anti-CD122 IgG antibody HuABC2.
July 5, 2016
A new U.S. patent (9382319) was issued for JN Bioscience' MultYmab™ antibody engineering platform, which strengthens the company's IP position for application of this technology to generate potent agonist antibodies against costimulatory molecules for cancer immunotherapy.
June 13, 2016
The therapeutic efficacy of HuABC2, a humanized anti-CD122 IgG antibody, for prevention of renal allograft rejection in non-human primates was orally presented by Dr. Andrew Adams' group of Emory University at the American Transplant Congress in Boston MA (click here for the abstract).
